CN107137701A - 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 - Google Patents
一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 Download PDFInfo
- Publication number
- CN107137701A CN107137701A CN201710314783.4A CN201710314783A CN107137701A CN 107137701 A CN107137701 A CN 107137701A CN 201710314783 A CN201710314783 A CN 201710314783A CN 107137701 A CN107137701 A CN 107137701A
- Authority
- CN
- China
- Prior art keywords
- socs2
- vaccines
- inhibitor
- exogenous peptide
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 17
- 229960005486 vaccine Drugs 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title abstract description 31
- 229940029030 dendritic cell vaccine Drugs 0.000 title abstract description 12
- 201000007270 liver cancer Diseases 0.000 title abstract description 9
- 208000014018 liver neoplasm Diseases 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 title abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 33
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims abstract description 29
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims abstract description 25
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 101150107526 Socs2 gene Proteins 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 230000005909 tumor killing Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 230000035800 maturation Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102100022297 Integrin alpha-X Human genes 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CGVWDTRDPLOMHZ-FXQIFTODSA-N Gln-Glu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O CGVWDTRDPLOMHZ-FXQIFTODSA-N 0.000 description 1
- HLYCMRDRWGSTPZ-CIUDSAMLSA-N Glu-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CS)C(=O)O HLYCMRDRWGSTPZ-CIUDSAMLSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- INXAPZFIOVGHSV-CIUDSAMLSA-N Pro-Asn-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 INXAPZFIOVGHSV-CIUDSAMLSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种提高DC疫苗抗肝癌效果的基因靶标、抑制剂和DC肿瘤疫苗。本发明证明，通过siRNA抑制DC中SOCS2表达可以显著提高DC疫苗的体内抑瘤效果，而本发明提供的外源肽为DC中SOCS2表达的有效抑制剂，具有与siRNA相似的功能，可以显著提高DC疫苗的体内抑瘤效果。使用SOCS2的表达抑制剂和本发明提供的外源肽可以用于制备更优抗肝癌效果的DC肝癌疫苗。
Description
技术领域
本发明属于基因治疗和免疫治疗领域，具体涉及一种提高DC疫苗抗肝癌效果的基因靶标、抑制剂和DC肿瘤疫苗。
背景技术
肝细胞癌是全世界最常见的恶性肿瘤之一，每年约有60万患者被诊断出患有肝细胞癌。目前，对于肝细胞癌的治疗主要是手术切除、肝脏移植、放化疗等，但仅有20％的患者能够被治疗。我国肝细胞癌年死亡率占肿瘤死亡率的第2位。肝细胞癌的病因及发病机制尚未确定，因此，寻找新的肝细胞癌的治疗靶点和药物是研究重点。
基于DC的生物治疗格外引人瞩目。理论上说，DC是激发适应性免疫最有效的APC，将其在体外荷载肿瘤抗原后回输，荷肽DC通过MHC/抗原肽-TCR的相互作用激活特异性T细胞，从而启动抗瘤免疫应答，预防或者清除肿瘤。这种方法安全而少副作用，对微小和转移病灶更有传统手段无可比拟的高度靶向性。但实际运用时，仅仅荷肽的DC往往并不能激发足够强大的抗瘤免疫应答，所以治疗效果不如预期理想。这是由于为躲避宿主免疫系统攻击，肿瘤发展出多种多样的逃逸机制，在抗原提呈阶段，就可能存在肿瘤抗原免疫原性低下、MHC分子表达减少、协同刺激分子缺如、分泌抑制性细胞因子等因素。因此，为提高疫苗的效能，就必须采取一定的方法来修饰、处理DC，增强其抗原提呈能力。
发明内容
本发明目的在于提供一种提高DC疫苗抗肝癌效果的基因靶标、抑制剂和DC肿瘤疫苗。
实现本发明上述目的技术方案如下：
基因SOCS2作为靶标在制备DC肝癌疫苗方面的应用。
基因SOCS2的抑制剂在制备DC肝癌疫苗方面的应用。
优选地，所述抑制剂为抑制基因SOCS2表达的siRNA或含抑制基因SOCS2表达的siRNA序列的载体。
优选地，所述抑制剂为SEQ ID NO.1所示的外源肽。
优选地，所述外源肽N和/或C末端被化学修饰。
优选地，所述外源肽的N末端被乙酰化修饰，C末端被酰胺化修饰。
优选地，所述外源肽为游离形式或药学上可以接受的成盐形式，包括盐酸盐、硫酸盐、磷酸盐、磺酸盐、乙酸盐、柠檬酸盐和酒石酸盐。
一种生物制品，含有上述抑制剂。
上述生物制品在制备DC肝癌疫苗方面的应用。
一种DC肝癌疫苗，其DC细胞的SOCS2基因低表达。
本发明的突出优点：
本发明证明，通过siRNA抑制DC中SOCS2表达可以显著提高DC疫苗的体内抑瘤效果，而本发明提供的外源肽为DC中SOCS2表达的有效抑制剂，具有与siRNA相似的功能，可以显著提高DC疫苗的体内抑瘤效果。使用SOCS2的表达抑制剂和本发明提供的外源肽可以用于制备更优抗肝癌效果的DC肝癌疫苗。
附图说明
图1为各组成熟DC中SOCS2 mRNA的相对表达量；
图2为各组成熟DC接种20天后对荷瘤裸鼠的体内抑瘤率(％)。
具体实施方式
下面就结合实施例具体介绍本发明的实质性内容，由于篇幅原因，实验过程的描述无法做到非常详细，凡是实验中未详细描述的部分均为本领域技术人员熟知的常规操作。
一、实验材料
人肝细胞株瘤细胞株HHCC购于美国ATCC，并有本公司保存。将HHCC细胞复苏后接种于培养瓶中，加入含有10％FBS的RPMI-1640，贴壁细胞用0.25％的胰酶消化。取对数生长期的细胞进行实验。Balb/c小鼠购于南京君科生物工程有限公司。
本发明外源肽通过本领域公知的标准多肽固相合成技术合成，采用芴甲氧羰基(Fmoc)N端保护策略。按照树脂固相合成的方法依次连接相应氨基酸，期间依次脱去Fmoc-保护基团，然后切肽，获得粗品，粗品经C18柱分离纯化，HPLC和MS检测确证了本发明外源肽的结构，且纯度均≥98％。其氨基酸序列如下(N末端→C末端)，末端未经化学修饰：
QEDLMGPNQTDGEPC(SEQ ID NO.1)
二、实验方法
1、细胞培养和肿瘤裂解物的制备
人肝细胞株瘤细胞株HHCC购于美国ATCC，并由本公司保存。将HHCC细胞复苏后接种于培养瓶中，加入含有10％FBS的RPMI-1640，贴壁细胞用0.25％的胰酶消化。取对数生长期的细胞进行实验。Balb/c小鼠购于南京君科生物工程有限公司。
肿瘤裂解物的制备：将HHCC细胞接种于含有10％FBS的RPMI-1640的培养瓶中，待贴壁达到80％时，取贴壁细胞，用PBS洗涤重悬至3×107/mL，经-80℃/37℃反复冻融5次，超声波裂解1次，离心收集上清即得肿瘤裂解物，冷冻干燥。
2、BM-DC的培养
参考Garrigan等人方法：RPMI-1640冲洗小鼠长骨髓腔获得骨髓细胞，Tirs-NH4裂解去除红细胞，用含10％FCS、20ng/ml rmGM-CSF(R&D)的RPMI-1640完全培养基重悬至3×106细胞/ml，1ml/孔接种至24孔培养板，37℃、5％CO2培养。每隔2-3d，轻轻吹打，3/4量换液以去除悬浮细胞，并补液至原体积。5～7d后，收集悬浮和松散贴壁的细胞即为未成熟的树突状细胞(iDC)。
3、外源肽和siRNA沉默SOCS2基因表达
siRNA沉默组：收集培养第6天的iDC，转染有绿色荧光染料FAM标记、针对SOCS2mRNA的siRNA(委托上海吉玛设计合成)，步骤如下：按每孔3μl FAM-siRNA、3μlGeneporter(Gene Therapy Systems)、96μl无血清RPMI-1640混合，接种至12孔培养板，25℃孵育30min。随后，用无血清RPMI-1640重悬iDC至2×106细胞/ml，以1ml/孔加入孵育有转染试剂的12孔培养板，37℃孵育4h；最后，每孔加入1ml含10％FCS、20ng/ml rmGM-CSF的RPMI-1640完全培养基，37℃孵育8h。
外源肽沉默组：收集培养第6天的iDC，不转染siRNA，于12孔培养板中以含10％FCS、20ng/ml rmGM-CSF的RPMI-1640完全培养基调整成与siRNA沉默组终体积相同、细胞浓度相同的培养体系，但是培养基中含终浓度为10μM的外源肽，37℃孵育8h。
阴性对照组：同外源肽沉默组，但是培养基中不含外源肽，37℃孵育8h。
4、DC荷载肿瘤裂解物与LPS刺激成熟
未沉默和沉默SOCS2的iDC用含肿瘤裂解物(200μg/ml))、LPS(100ng/ml)的RPMI-1640完全培养基重悬至2×106细胞/ml，1ml/孔接种至24孔板，37℃孵育24h以成熟。其中，未沉默SOCS2者标记为NSI-DC，siRNA沉默者标记为SSI-DC，外源肽沉默者标记为PSI-DC。通过流式法检测检测CD11c、CD80、CD86的表达检测DC纯度和成熟度。
5、RT-PCR检测DC中SOCS2 mRNA表达
用Trizol法提取NSI-DC、SSI-DC、PSI-DC的总RNA。采用两步法RT-PCR，参照TaKaRa公司AMV反转录酶说明书进行反转录。cDNA的PCR反应体系如下：2μL反转录产物，5μL的10×PCR Buffer(Mg2+Free)，3μL MgCl2(25mmol/l)，4μL的dNTP Mixture(2.5mmol/L)，0.25μL的Taq酶(5U/μl)，上下引物各1μL(l20μmol/l)，加灭菌蒸馏水调至50μl体系。选用小鼠GAPDH作内参，引物序列如下：
SOCS2上游引物：5’-AGCTCGGTCAGACAGGATGG-3’(SEQ ID NO.2)
SOCS2下游引物：5’-TTCGAAGATTAGTTGGTCCAGC-3’(SEQ ID NO.3)
GAPDH上游引物：5’-ATATGGTACGCGAGGTGAGG-3’(SEQ ID NO.4)
GAPDH下游引物：5’-GTGATTTTAGGGACGCTCCA-3’(SEQ ID NO.5)
PCR产物在1.5％琼脂糖凝胶上电泳，GV染色后紫外线投射仪下观察结果，经凝胶扫描成像系统拍照，用Quantityone软件半定量分析结果，即SOCS2 mRNA条带的灰度值/GAPDH条带的灰度值，取平均值进行统计学分析。
7、荷瘤动物的建模与治疗
Balb/c小鼠于右背部皮下接种HHCC细胞1×106/只，接种2周后成瘤率100％，瘤径约5mm。将成瘤裸鼠随机分为4组：siRNA沉默组、外源肽沉默组、阴性对照组和空白对照组，每组10只。从第15天开始，siRNA沉默组、外源肽沉默组、阴性对照组每2天分别于皮下注射SSI-DC、PSI-DC、NSI-DC的灭菌PBS悬液(1×106/50μL)，空白对照组注射等量灭菌PBS，连续注射4次。为了充分促进机体免疫反应，每次注射DC或PBS后再腹腔注射LPS，每只每次30μg/200μL。第25天开始(接种DC第10天)，游标卡尺每2天测一次肿瘤体积。接种DC 20天后，处死小鼠，剥离肿瘤块，计算siRNA沉默组、外源肽沉默组、阴性对照组相对于空白对照组的肿瘤抑制率(％)，公式：肿瘤抑制率(％)＝(空白对照组体积-siRNA沉默组/外源肽沉默组/阴性对照组体积)/空白对照组体积×100％。
8、数据处理
数据分析采用SPSS20.0软件进行，数据表示方法为均值±标准差，组间比较采用t检验，P<0.05认为有统计学差异。
三、实验结果
1、各组DC纯度和成熟度
CD11c是小鼠髓系来源DC的特异性标志，各组DC的CD11c均呈阳性表达，且纯度在80％以上。CD80、CD86是与DC抗原呈递相关的标志分子，成熟前均低表达，但成熟后均显著高表达，其中，成熟DC的CD80的纯度均在80％以上，CD86的纯度均在50％以上。
结果表明，NSI-DC、SSI-DC、PSI-DC均为成熟的DC细胞。
2、各组成熟DC中SOCS2 mRNA表达
与阴性对照组NSI-DC相比，siRNA沉默组SSI-DC、外源肽沉默组PSI-DC中的SOCS2mRNA表达显著下调(P<0.05)，各组SOCS2 mRNA相对表达量见表1和图1。
表1各组成熟DC中SOCS2 mRNA的相对表达量
| 组别 | SOCS2 mRNA相对表达量 |
| 阴性对照组 | 1.24 |
| siRNA沉默组 | 0.32 |
| 外源肽沉默组 | 0.39 |
3、各组成熟DC对荷瘤裸鼠的体内抑瘤率(％)
与阴性对照组NSI-DC相比，siRNA沉默组SSI-DC、外源肽沉默组PSI-DC对荷瘤裸鼠的体内抑瘤率显著升高，肿瘤生长缓慢，具有明显的抑制作用。各组成熟DC接种20天后对荷瘤裸鼠的体内抑瘤率(％)见表2和图2。
表2各组成熟DC接种20天后对荷瘤裸鼠的体内抑瘤率(％)
| 组别 | 体内抑瘤率(％) |
| 阴性对照组 | 35 |
| siRNA沉默组 | 73 |
| 外源肽沉默组 | 67 |
实验证明，通过siRNA抑制DC中SOCS2表达可以显著提高DC疫苗的体内抑瘤效果，而本发明提供的外源肽为DC中SOCS2表达的有效抑制剂，具有与siRNA相似的功能，可以显著提高DC疫苗的体内抑瘤效果。使用SOCS2的表达抑制剂和本发明提供的外源肽可以用于制备更优抗肝癌效果的DC肝癌疫苗。
上述实施例是对本发明实质性内容的体现，用于更好地解释本发明，但本领域技术人员应当知晓，不应将本发明的保护范围局限于上述具体的实施例。
SEQUENCE LISTING
<110> 南京盖斯夫医药科技有限公司
<120> 一种提高DC疫苗抗肝癌效果的基因靶标、抑制剂和DC肿瘤疫苗
<130> 1
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 15
<212> PRT
<213> 人工序列
<400> 1
Gln Glu Asp Leu Met Gly Pro Asn Gln Thr Asp Gly Glu Pro Cys
1 5 10 15
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<400> 2
agctcggtca gacaggatgg 20
<210> 3
<211> 22
<212> DNA
<213> 人工序列
<400> 3
ttcgaagatt agttggtcca gc 22
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<400> 4
atatggtacg cgaggtgagg 20
<210> 5
<211> 20
<212> DNA
<213> 人工序列
<400> 5
gtgattttag ggacgctcca 20
Claims (10)
1.基因SOCS2作为靶标在制备DC肝癌疫苗方面的应用。
2.基因SOCS2的抑制剂在制备DC肝癌疫苗方面的应用。
3.根据权利要求2所述的应用，其特征在于：所述抑制剂为抑制基因SOCS2表达的siRNA或含抑制基因SOCS2表达的siRNA序列的载体。
4.根据权利要求2所述的应用，其特征在于：所述抑制剂为SEQ ID NO.1所示的外源肽。
5.根据权利要求4所述的应用，其特征在于：所述外源肽N和/或C末端被化学修饰。
6.根据权利要求5所述的应用，其特征在于：所述外源肽的N末端被乙酰化修饰，C末端被酰胺化修饰。
7.根据权利要求4所述的应用，其特征在于：所述外源肽为游离形式或药学上可以接受的成盐形式，包括盐酸盐、硫酸盐、磷酸盐、磺酸盐、乙酸盐、柠檬酸盐和酒石酸盐。
8.一种生物制品，其特征在于：含有权利要求2-7任一所述的抑制剂。
9.权利要求8所述的生物制品在制备DC肝癌疫苗方面的应用。
10.一种DC肝癌疫苗，其特征在于：其DC细胞的SOCS2基因低表达。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710314783.4A CN107137701B (zh) | 2017-05-07 | 2017-05-07 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710314783.4A CN107137701B (zh) | 2017-05-07 | 2017-05-07 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107137701A true CN107137701A (zh) | 2017-09-08 |
| CN107137701B CN107137701B (zh) | 2020-07-14 |
Family
ID=59778644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710314783.4A Active CN107137701B (zh) | 2017-05-07 | 2017-05-07 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107137701B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101437834A (zh) * | 2004-07-19 | 2009-05-20 | 贝勒医学院 | 细胞因子信号转导调节剂的调节和用于免疫治疗的应用 |
| CN101501055A (zh) * | 2005-06-23 | 2009-08-05 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
| US20100255023A1 (en) * | 2007-11-30 | 2010-10-07 | Si-Yi Chen | Dendritic cell vaccine compositions and uses of same |
| WO2012156473A2 (en) * | 2011-05-16 | 2012-11-22 | University Of Tartu | A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit |
| US20130317087A1 (en) * | 2011-02-09 | 2013-11-28 | University Of Rochester | Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements |
| CN104508149A (zh) * | 2012-07-27 | 2015-04-08 | 诺华股份有限公司 | 对jak/stat抑制剂治疗响应的预测 |
| CN105247371A (zh) * | 2013-06-17 | 2016-01-13 | 德国癌症研究公共权益基金会 | 通过转录因子tsc22d4的抑制剂治疗胰岛素抵抗 |
-
2017
- 2017-05-07 CN CN201710314783.4A patent/CN107137701B/zh active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101437834A (zh) * | 2004-07-19 | 2009-05-20 | 贝勒医学院 | 细胞因子信号转导调节剂的调节和用于免疫治疗的应用 |
| CN101501055A (zh) * | 2005-06-23 | 2009-08-05 | 贝勒医学院 | 负性免疫调节因子的调节和免疫疗法应用 |
| US20100255023A1 (en) * | 2007-11-30 | 2010-10-07 | Si-Yi Chen | Dendritic cell vaccine compositions and uses of same |
| CN101932339A (zh) * | 2007-11-30 | 2010-12-29 | 贝勒医学院 | 树突细胞疫苗组合物及其应用 |
| US20130317087A1 (en) * | 2011-02-09 | 2013-11-28 | University Of Rochester | Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements |
| WO2012156473A2 (en) * | 2011-05-16 | 2012-11-22 | University Of Tartu | A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit |
| CN104508149A (zh) * | 2012-07-27 | 2015-04-08 | 诺华股份有限公司 | 对jak/stat抑制剂治疗响应的预测 |
| CN105247371A (zh) * | 2013-06-17 | 2016-01-13 | 德国癌症研究公共权益基金会 | 通过转录因子tsc22d4的抑制剂治疗胰岛素抵抗 |
Non-Patent Citations (4)
| Title |
|---|
| GENBANK: ""MULTISPECIES: DNA polymerase III subunit gamma/tau[Aerococcus]，ACCESSION WP_070431481 "", 《GENBANK》 * |
| JIN HU ET AL.: ""SOSC2 Influences LPS Induced Human Monocyte-Derived Dendritic Cell Maturation"", 《PLOS ONE》 * |
| 师文楷: ""SOCS-2和STAT-5在肝细胞癌组织中的表达及临床意义"", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 王莉等: ""树突状细胞肿瘤疫苗研究进展"", 《癌症进展杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107137701B (zh) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA030061B1 (ru) | Фармацевтические композиции и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток | |
| CN106892974A (zh) | 一种基于肿瘤抗原ecm1的长肽ere1及其在肿瘤免疫治疗中的应用 | |
| CN107137701A (zh) | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 | |
| CN102898508B (zh) | 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途 | |
| CN107206061A (zh) | 多剂量注射用树突状细胞疫苗的制备,用于阻断her2和her3的联合治疗和雌激素受体阳性her2乳腺癌治疗 | |
| CN101863984B (zh) | GM-CSF/TNF-α膜表面修饰的前列腺癌治疗性疫苗 | |
| CN105233279A (zh) | 神经胶质瘤全肿瘤抗原及其制备方法和应用 | |
| CN109414023A (zh) | 用嵌合脊髓灰质炎病毒激活抗原呈递细胞的组合物和方法 | |
| CN105087649A (zh) | 携带muc-1抗原基因的重组腺相关病毒载体及构建方法与应用 | |
| CN107188959B (zh) | 抗原肽t790m-6及其在制备治疗非小细胞肺癌的药物中的应用 | |
| CN107188958B (zh) | 抗原肽t790m-5及其在制备治疗非小细胞肺癌的药物中的应用 | |
| CN107188955A (zh) | 抗原肽t790m‑3及其在制备治疗非小细胞肺癌的药物中的应用 | |
| CN107325172A (zh) | 抗原肽t790m‑2及其在制备治疗非小细胞肺癌的药物中的应用 | |
| WO2013084250A1 (en) | Combination of cyclophosphamide and dendritic cells for use in the treatment of uterine cervix carcinoma | |
| US20230405111A1 (en) | Ebv-targeted allogeneic b cell vaccine and preparation method therefor | |
| CN106591248B (zh) | 重组溶瘤流感病毒制备方法和应用 | |
| CN106540247A (zh) | 肿瘤通用型成纤维细胞疫苗及其制备方法和用途 | |
| CN109081873A (zh) | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 | |
| CN105177047A (zh) | 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用 | |
| CN105219706B (zh) | 促牙周膜间充质干细胞分泌抗炎因子的培养液及方法 | |
| CN117904199A (zh) | 一种p53与免疫检查点联合的融合基因载体及其在制备抗肿瘤生物药品中的应用 | |
| KR20220067519A (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 CD103+ Fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
| WO2018188235A1 (zh) | 一种乙肝病毒抗原肽联合肝癌细胞抗原信息的抗原提呈信号群及其应用 | |
| CN104388466A (zh) | 一种复制缺陷性重组腺病毒rAd-RNAi-SOCS1及其制备方法和其在治疗肿瘤中的用途 | |
| CN1212153C (zh) | 一种来源于植物的免疫佐剂及其制法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200615 Address after: 261000 hi tech Industrial Development Zone, Weifang, Shandong, Gaomi City Applicant after: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Address before: 211198 No. 18 Zhilan Road, Science Park, Jiangning District, Nanjing City, Jiangsu Province Applicant before: NANJING GAISIFU MEDICAL TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A gene target, inhibitor and DC tumor vaccine for improving the anti hepatoma effect of DC vaccine Effective date of registration: 20200917 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980006170 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210914 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020980006170 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A gene target, inhibitor and DC tumor vaccine for improving the anti liver cancer effect of DC vaccine Effective date of registration: 20210915 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021370010092 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220905 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY CO.,LTD. Registration number: Y2021370010092 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A gene target, inhibitor and DC tumor vaccine to improve the effect of DC vaccine against liver cancer Effective date of registration: 20220906 Granted publication date: 20200714 Pledgee: Shandong Gaomi rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG XINRUI BIOTECHNOLOGY CO.,LTD. Registration number: Y2022370010139 |